The settlement agreement resolves all outstanding patent litigation relating to AUVELITY.

Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Investing.com - Axsome Therapeutics (NASDAQ:AXSM) Inc reported on Monday third quarter earnings that beat analysts' forecasts and revenue that topped expectations. Axsome ...

On Monday, BofA Securities analyst Jason Gerberry increased the price target for Axsome Therapeutics (NASDAQ ... to challenge the patents in the future, the analyst expressed confidence in ...

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial ...

UBS analysts increased the price target on Axsome Therapeutics (NASDAQ:AXSM) shares to $133.00, up from the previous $105.00, while maintaining a Buy rating on the stock. The company, currently valued ...

Short interest in Axsome Therapeutics Inc (NASDAQ:AXSM) decreased during the last reporting period, falling from 6.62M to 5.75M. This put 14.22% of the company's publicly available shares short.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

It's been a strong day for Axsome Therapeutics. Its shares are now trading at $127.02, marking a 20.1% change since the ...

Patent Secures Protection for RLF-TD011 in Epidermolysis Bullosa Wound Treatment GENEVA, SWITZERLAND / ACCESS Newswire / February 11, 2025 /RELIEF THERAPEUTICS Holding SA(SIX:RLF) (OTCQB ...

Sources: FactSet, Tullett Prebon Commodities & Futures: Futures prices are delayed at least 10 minutes as per exchange requirements. Change value during the period between open outcry settle and ...